Skip to main content
OpenTrials
Completed

NCT Number: NCT01259271

Selective Nerve Stimulation (SNS) Pilot Study

The purpose of this study is to examine if a new device, the SNS (Selective Nerve Stimulator), is effective in changing the way nerves work as pain killing drugs sometimes do. During this study, the study team will place 2 adhesive patches on the inside of one of the wrists of the non-dominant hand (if the subject is right-handed the electrodes will be placed on the subject's left wrist) of the study subject. These patches will be connected by wires (leads) to a small box with a headphone jack. This is designed to provide gentle electrical stimulation through the skin. This study will look at the amount of change from normal nerve function, the sensory effects (feeling, sensations in the body), and any changes the subject has when performing the 2 hour tests. The safety of the study device will also be evaluated.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Early Phase 1

Primary location

Codman & Shurtleff

Raynham, Massachusetts, 02767, United States

About this study

Single center, single blind, randomized, crossover design, sham controlled pilot study using Selective Nerve Stimulation (SNS) signal for nerve modulation with three amplitudes (supra-threshold,sub-threshold and sham)

The primary objective of this proof of concept study is to:

  • Evaluate median nerve modulation with selective nerve stimulation amplitudes (supra-threshold, sub-threshold, and sham) by means of objective quantitative sensory tests (QST) and Sensory Nerve Conduction Threshold Tests (sNCTs) in healthy subjects.

The secondary objectives to be evaluated in this study are to:

  • Establish device safety profile
  • Evaluate patient reported sensory descriptions and perception during modulation

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Subjects must fulfill all of the following criteria:

  • 18 years of age or older
  • Ability to provide written informed consent for participation in this study
  • Ability to understand and willing to comply with all study-related procedures, such as questionnaires, diaries and follow-up visits for the study duration
  • Ability to not use analgesics throughout the duration of the study

Exclusion criteria

  • Chronic peripheral pain or diagnosed neuropathy of the median nerve or the cervical spine (C6-C8) as reported by the subject
  • Use of analgesics within 3 days prior to screening / baseline visit and if the subject is unable to refrain from using any analgesics throughout their study participation
  • Metal implants in the forearm
  • Previous nerve damage or bone injury that led to median nerve damage
  • Previous surgery for carpal tunnel release in the non-dominant study hand
  • Skin irritation or active infection at or near the electrode placement sites
  • Allodynia involving the patch application area
  • Known history of allergic reaction to the adhesive, hydrogel or any other component of the electrode or patch
  • Use of an investigational drug or device within 30 days prior to study enrollment.
  • Use of Cardiac pacemaker, implantable cardioverter-defibrillators (ICD's), or other electrostimulation device
  • Currently untreated abuse of drugs and/or alcohol
  • Psychological or medical condition that would make the study participant unadvisable
  • Uncontrolled seizures (averaging > 2 seizures/month)
  • Pregnant, or planning on becoming pregnant or breastfeeding during the study period
  • Co-morbid condition that could limit his/her ability to participate in the study or to comply with the follow-up requirements.
  • Any known inabilities to be evaluated instrumentally by quantitative sensory testing (QST) or sensory nerve conduction threshold tests (sNCTs) for a median nerve neuropathy

Treatment and study plan

Selective Nerve Stimulation (SNS) stimulator device

Device

Two hours per study visit separated by a minimum of a 20 hour wash out period between stimulations.

Other names: Transdermal Amplitude Modulated Signal nerve stimulation device (TAMS)

Primary outcomes

  1. Modulation of Median Nerve Perception or Nerve Physiology

    Time frame: > 2 weeks

    The primary effectiveness endpoints are the modulation of median nerve perception or nerve physiology as measured by:

    • QST evaluated by method of levels for vibratory perception threshold (VS) in ABeta fibers and for cold sensation threshold (CS) in alpha gamma fibers and warm sensation threshold (WS) in c fibers.
    • sNCTs Current Perception Threshold (CPT) in ABeta, Alpha gamma and c fibers (CPT2k, CPT250, CPT5 respectively).

Sponsors and collaborators

Lead sponsor

Codman & Shurtleff

Industry

Registry information

Official study title

Single Center, Single Blind, Randomized, Sham Controlled Pilot Study Using Selective Nerve Stimulation (SNS) Signal for Nerve Modulation With Three Amplitudes (Supra-threshold, Sub-threshold and Sham)

Acronym: SNS

Important dates

Study start
2010
Primary completion
2011
Study completion
2011
First posted
Dec 14, 2010
Registry last updated
Oct 18, 2019

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.